Roche announced the global launch of AXELIOS 1, their next‑generation single-molecule sequencing platform and the first powered by proprietary sequencing by expansion (SBX) technology.

AXELIOS 1 aims to combine accuracy, speed, flexibility, scalability, and cost efficiency to addresses critical bottlenecks in genomics and potentially in clinical research. AXELIOS 1 will enable researchers to make significant discoveries that enhance our understanding of diseases, with the potential to replace existing technologies in pivotal research areas.

The AXELIOS 1 platform’s flexible sequencing run setup and high-throughput effortlessly handle everything from small-scale studies to massive genomic projects, ensuring laboratories can expand their research capabilities with a single instrument. For researchers, this flexible and open setup grants broader freedom of exploration and new workflows that can truly expand our knowledge of complex diseases. 

Axelios 1 is for Research Use Only and not commercially available in the United States. Not for use in diagnostic procedures. 

Visit Roche for more information